What is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (600196.SS) StockRank?

MoatMap's StockRank for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) is 42/100, with a Hold signal. This is a composite score combining Quality (52), Value (51), and Momentum (30) factor ranks across MoatMap's 20,000+ stock universe.

Does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have an economic moat?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) is Hold, based on a StockRank of 42/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600196.SS

Hold

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. · Healthcare · China · $9.1B · Avg Vol: $106M/d

StockRank

Get insider-trade alerts

P/E (TTM)

17.9x

ROE

7.0%

D/E

0.6x

Dividend %

1.7%

COMPANY DESCRIPTION

Shanghai Fosun Pharmaceutical is a leading, globally integrated healthcare group covering pharmaceutical R&D, manufacturing, medical devices, and hospital operations. The company is distinguished by its strong innovation pipeline, strategic international partnerships (such as with BioNTech), and active venture investments. Its diversified business model and global footprint mitigate regulatory risks in the domestic market.

FINANCIAL SUMMARY (CNY)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	44.0B	41.4B	41.1B	41.7B	-1.8%	42.4B	43.3B	44.4B	3.2%
EPS (CNY)	1.43	0.89	1.04	1.27	-3.9%	1.28	1.48	1.66	14.3%
Shares	2.7B	2.7B	2.7B	2.7B	-0.1%	2.1B	—	—	—
Debt	30.2B	35.1B	36.2B	38.1B	8.0%	39.6B	—	—	—
Equity	44.6B	45.7B	47.3B	48.7B	3.0%	—	—	—	—
Op CF	4.2B	3.4B	4.5B	5.2B	7.3%	5.3B	—	—	—
Inv CF	-4.1B	-3.8B	-3.6B	-2.1B	—	—	—	—	—
Fin CF	4.4B	-1.3B	-1.0B	-3.2B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-4.1%

SMA 50SMA 200

$3.38

RSI (14)

40.5

52W High

$4.84

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

7.6%66.0

ROE

7.0%63.3

GP/Assets

17.9%42.7

Op. Margin

8.1%60.6

FCF/Assets

0.6%48.0

Piotroski

784.2

Int. Cover

5.0x53.0

D/E Ratio

0.62x25.8

Current Ratio

0.93x9.5

Value

P/E (TTM)

17.9x63.9

EV/EBITDA

16.1x43.4

P/FCF

81.2x17.3

P/B

1.2x78.2

P/S

1.4x75.9

Div Yield

1.7%41.7

Momentum

52W High %

70%48.4

RS 6M

—N/A

SMA 50/200

0.92x41.3

EPS Rev 4W

-20.5%4.4

EPS Rev 12W

-20.4%6.9

EPS Improve

-14%16.9

Q Growth

14%51.8

FUNDAMENTALS

Market Cap

$9.1B

P/E (Forward)

20.8x

Gross Margin

50.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600196.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600196.SS	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(you)	$9.1B	42	Hold
000661.SZ	Changchun High-Tech Industry (Group) Co., Ltd.	$4.8B	34	Sell
002294.SZ	Shenzhen Salubris Pharmaceuticals Co., Ltd.	$5.3B	30	Sell
688131.SS	Shanghai Haoyuan Chemexpress Co., Ltd.	$3.1B	41	Hold
300558.SZ	Betta Pharmaceuticals Co., Ltd.	$3.1B	44	Hold
002317.SZ	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	$3.2B	38	Hold
6887.HK	Sunshine Lake Pharma Co., Ltd.	$2.9B	45	Hold
300199.SZ	Hybio Pharmaceutical Co., Ltd.	$3.1B	37	Hold
600521.SS	Zhejiang Huahai Pharmaceutical Co., Ltd.	$3.7B	32	Sell
300142.SZ	Walvax Biotechnology Co., Ltd.	$3.4B	51	Hold

Peer medians: ROE 4.5% · P/E 29.0x · Gross margin 52.6%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS): Stock Score Summary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) has a MoatMap StockRank of 42/100 based on Quality (52/100), Value (51/100), and Momentum (30/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$3.38
Market Cap	$9.1B
P/E (TTM)	17.86
P/E (Forward)	20.78
Price/Book	1.23
Return on Equity	7.0%
Return on Invested Capital	7.6%
Debt/Equity	0.62x
Gross Margin	50.3%
Operating Margin	8.1%
Revenue Growth	6.9%
Dividend Yield	1.7%
Free Cash Flow	$113M

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s (600196.SS) StockRank?: MoatMap’s StockRank for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) is 42/100, with a Hold signal. It is a composite of Quality (52), Value (51), and Momentum (30) factor ranks across MoatMap’s 20,000+ stock universe.
Does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have an economic moat?: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) is Hold, based on a StockRank of 42/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in?: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).